Dengue in the Dominican Republic: Epidemiology for 2004

Microscopy Research and Technique

Volumn 68, Issue 3-4, 2005, Pages 250-254

  Cabrera Batista, Brinia ^a,b   Skewes Ramm, Ronald ^c   Fermin, Cesar D ^d   Garry, Robert F ^d  

^a Dominican Republic Directorate of Epidemiology (DGEPI)   (Dominican Republic)

^b UNIVERSIDAD TECNOLÓGICA DE SANTIAGO   (Dominican Republic)

^c Secretaría de Estado de Salud Pública   (Dominican Republic)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Dengue clinical presentations; Dengue serotypes; Epidemiology; Surveillance program; The Dominican Republic

Indexed keywords

EPIDEMIOLOGY;

CLINICAL PRESENTATIONS; DENGUE CLINICAL PRESENTATION; DENGUE FEVERS; DENGUE HEMORRHAGIC FEVER; DENGUE SEROTYPE; DENGUE VIRUS; SEROTYPES; SURVEILLANCE PROGRAM; THE DOMINICAN REPUBLIC; VIRUS-1;

VIRUSES;

ARTICLE; CLIMATE; DENGUE; DENGUE VIRUS; DISEASE TRANSMISSION; DOMINICAN REPUBLIC; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; VIRUS INFECTION; VIRUS ISOLATION; VIRUS TRANSMISSION;

DENGUE VIRUS;

EID: 28144464155     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.20225     Document Type: Article

References (19)

1. Barrett AD. 2001. Current status of flavivirus vaccines. Ann N Y Acad Sci 951:262-271.
2. Benenson AS. 1997. Manual de Control de las enfermedades transmisibles. Washington, DC: OPS/OMS (Publicación Scientífica). p. 564.
3. Bhamarapravati N, Sutee Y. 2000. Live attenuated tetravalent dengue vaccine. Vaccine 18(Suppl 2):44-47.
4. Edelman R, Wasserman SS, Bodison SA, Putnak EJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69(Suppl 6):48-60.
5. Encarta. 2005. Republics Dominicana. Enciclopedia Microsoft® Encarta® Online 2005 ed: Microsoft Corporation.
6. Gratz NG. 2004. Critical review of the vector status of Aedes albopictus. Med Vet Entomol 18:215-227.
7. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP. 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298:146-159.
8. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T. 2004. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78:4761-4775.
9. Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, Yoksan S, Luxemburger C, Lang J. 2004. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22:3563-3574.
10. Halstead SB. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
11. Herrera E, Ferrand C. 2000. 2. Situación del Clásico y Hemorrágico en RD. Boletin Epidemiológico de la Dirección General de Epidemiología 14:3-6.
12. Hotta H, Sanchez LF, Takada H, Homma M, Kotani S. 1985. Enhancement of dengue virus infection in cultured mouse macrophages by lipophilic derivatives of muramyl peptidesi Microbiol Immunol 29:533-541.
13. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH, Jr. 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19:3179-3188.
14. Kanesa-Thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, Innis BL, Edelman R. 2003. Atypical antibody responses in dengue vaccine recipients. Am J Trop Med Hyg 69(Suppl 6):32-38.
15. OPS/OMS. 2003. Diagnóstico sobre el uso de boletines para la difusion de información epidemiológica en la Region de las Américas.
16. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. 1998. Dengue and dengue haemorrhagic fever. Lancet 352:971-977.
17. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF, Bhamarapravati N. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66:264-272.
18. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH, Jr, Innis BL. 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69(Suppl 6):24-31.
19. WHO. 2002. Dengue and dengue haemorrhagic fever. http://www. who.int/mediacentre/factsheets/fs117/en/.